News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
News AbbVie climbs post-Allergan M&A peak with Apogee buy AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.
News Bayer pledges $2.2bn to US manufacturing facility Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.